Analysis The Difference And Significance About TRAIL And DR5 In Before And After Chemotherapy

Objective:Recently,it is the most common female malignant tumor about of breast cancer,the studies of the treatment for breast cancer have advanced with the rising incidence of a disease Reference at home and abroad.The treatment of breast cancer has several Several methods:surgery and chemotherapy and endocrine therapy and combined application of targeted therapy,targeted therapy is a hotspot of research in recent years, a number of targeted therapy drugs has been developed. Herceptin that is one of targeted therapy is used widely in clinical about breast cancer,Since it was approved by the U.S. food and drug administration (FDA) in 1998.But it can only be applied to this patients of their Her-2 (++-+++) in tumor cell,there is not benefit for some people of Her -2(-) in tumor cell, at the same time,herceptin has certain cardiac toxicity、liver damage、kidney damage and other adverse reactions for patients.Tumor necrosis factor related apoptosis inducing ligand (tumor necrosis factor-related apoptosis inducing ligand, TRAIL) and its DR5 mediated tumor cell apoptosis has obvious advantages relative to other targeted therapy drugs such as herceptin,it can induced apoptosis of tumor cell, but don’t damaging to normal cells a,and what’ more,it is benefit for Her -2 (-).TRAIL as a member of the family of tumor necrosis factor distribute widespread in the patient’s cancer and normal tissue, TRAIL combine with death receptor DR4/DR5 corresponding mediated apoptosis of cancer cells in the human body. Such as TRAIL and anti-DR5 drugs that is artificial targeted therapy drugs is studying in phase II clinical trial,at the same time,some research shows that the synthesis of TRAIL and DR5 drugs have certain synergy with doxorubicin, paclitaxel, platinum and so on,the chemotherapy drugs can improve the expression level of TRAIL and DR5 in order to promote apoptosis of tumor cells by the synergistic effect.TRAIL and DR5 can improve killing effect of chemotherapy to the drug-resistant tumor cell.Current research stay in single medicine collaborate with TRAIL and DR5, there has been no reported about the collaborative of artificial TRAIL、anti-DR5 and TAC, and there is no certain theoretical about the collaborative.One of he purpose of this experiment is studying the collaborative between TAC chemotherapy regimens and TRAIL、DR5, In order to provide theoretical to TAC regimens and TRAIL、DR5 that will treatment breast cancer in the future.Presently, If we want to evaluate the efficacy of the patients with chemotherapy for a certain period after chemotherapy,we have to spend 5 years or 10 years to make long-term follow-up and survival analysis,But we are lack of prognosis indexes about the patients in certain period when they have been chemotherapyespecially postoperative patients are lack of visual changes in tumor size, so it is difficult to evaluate its postoperative effect of chemotherapy recently.So the second purpose of this experiment is TRAIL and DR5 can become efficacy understand when patients have been treated by TAC regimens, and it is prognostic factors of breast cancer.Methods:Randomly selected 40 cases of female breast cancer patients who have been confirmed by the breast surgery in affiliated hospital of Lu Zhou medical college,we extract peripheral venous blood in the after surgery and after the 6 times chemotherapy.Selection of 36 normal women for parallel comparison, interval 5 months take two peripheral blood was analyzed.The venous blood lymphocytes extracted that we can understand the change of the TRAIL and DR5 in peripheral blood by RNA extraction, reverse transcription cDNA, fluorescence quantitative PCR.Results:1. there is no statistically significant of difference expression quantity that TRAIL be in the peripheral blood of normal people for 5 months (tTRAIL= 1.014, P> 0.05);there is no statistically significant of difference expression quantity that DR5 be in the peripheral blood of normal people for 5 months (tDR5= 1.133, P> 0.05).2.The amount of expression TRAIL in peripheral blood increases 2.8 times when compared normal people and breast cancer patients, there is statistically significant difference (tTRAIL= 2.085, P< 0.05);Compared with patients with breast cancer, the expression quantity of DR5 in normal people raise 4.32 times, the difference is statistically significant (tDR5= 2.134, P< 0.05).3.TRAIL after chemotherapy raised 3.63 times compared with before treatment in breast cancer patients, expression difference was statistically significant (tTRAIL= 8.836, P< 0.001);DR5 expression after chemotherapy compared with before treatment quantity increases 14.25 times in breast cancer patients, statistically significant difference (tDR5= 8.97, P< 0.001).Conclusion:1.The fluctuation of TRAIL and DR5 in the peripheral blood in normal people is small,it is not statistical significance about the difference;observing the expression of TRAIL in normal is higher than tumor patient; DR5 in the normal peripheral blood is lower than tumor patients. There may is a certain relationship Low expression of TRAIL with the occurrence of tumor.2. TRAIL and DR5 after chemotherapy have different degree rise compared with before treatment for 6 cycles of chemotherapy by TAC regimens in breast cancer patients, showing that TAC and TRAIL/DR5 scheme has collaborative,this prompt TAC regimens can joint use with TRAIL and DR5 drugs.3.TRAIL and its receptors DR5 have collaborative relationships with TAC regimens,so we can preliminarily concluded that TRAIL and DR5 can become TAC chemotherapy regimens of recent curative effect evaluation index, the synergy of TRAIL and DR5 cannot determine TRAIL and DR5 become one of the prognostic factors of breast cancer.